title: Thrombin-activatable fibrinolysis inhibitor activity and global fibrinolytic capacity in Type 1 diabetes: evidence for normal fibrinolytic state.
abstract: Hypofibrinolysis is a state that is commonly observed in type 2 diabetic patients, a finding also possibly related to obesity and insulin resistance. There is little information, however, regarding the status of fibrinolytic system in Type 1 diabetes, in particular as reflected by thrombin-activatable fibrinolysis inhibitor (TAFI) activity and global fibrinolytic capacity (GFC). To provide information in this respect, 30 Type 1 diabetic patients (median age=16) and 28 healthy controls (median age=14) were enrolled in this study. The median duration of diabetes was 7 years, and median HbA(1c) was 8.85% (range: 5.5-11.9%) in the diabetic group. None of the patients had macrovascular complications. Microvascular complications were present in a total of eight patients (nephropathy: n=5; retinopathy: n=3). A comparison of the TAFI activity between the patient (median 84.9, range: 71.5-103.3%) and the control groups (median=83.3, range: 63.7-97.4%) yielded no statistically significant difference (P=.950). Similarly, GFC was comparable between the two groups (median=8.22, range: 0.72-22.38 microg/ml, and median=13.32, range: 3.0-23.22 microg/ml, respectively, in the diabetic and control groups, P=.086). TAFI activity did not significantly correlate with age, albumin excretion, fasting plasma glucose, HbA(1c), D-dimer, and fibrinogen by Spearman rank correlation test. There was as a significant inverse correlation between GFC and TAFI activity (r=-.414, P=.006). Contrary to the previous observations in Type 2 diabetes, our data suggest that fibrinolytic activity is not adversely affected by Type 1 diabetes, and it has no relationship with the degree of metabolic control.
authors.affiliation: Division of Endocrinology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara 06100, Turkey.
authors.forename: Ayla
authors.initials: A
authors.lastname: Harmanci
authors.forename: Nurgun
authors.initials: N
authors.lastname: Kandemir
authors.forename: Selcuk
authors.initials: S
authors.lastname: Dagdelen
authors.forename: Nazli
authors.initials: N
authors.lastname: Gonc
authors.forename: Yahya
authors.initials: Y
authors.lastname: Buyukasik
authors.forename: Ayfer
authors.initials: A
authors.lastname: Alikasifoglu
authors.forename: Serafettin
authors.initials: S
authors.lastname: Kirazli
authors.forename: Alev
authors.initials: A
authors.lastname: Ozon
authors.forename: Alper
authors.initials: A
authors.lastname: Gurlek
mesh_terms: D000293:Adolescent; D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D025901:Carboxypeptidase B2 / Q000097:blood*; D002648:Child; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000503:physiopathology*; D005260:Female; D005342:Fibrinolysis / Q000502:physiology*; D006801:Humans; D008297:Male
chemical_list: D001786:Blood Glucose; D025901:Carboxypeptidase B2